GRANT Tuesday, September 30, 2014- 11:45 BrightFocus Foundation Variable October 14, 2014 BrightFocus Foundation Alzheimer's Disease Research Award ...
THERAPEUTICS Eli Lilly & Co. N3pG-amyloid-beta Monoclonal Antibody Immunotherapy (passive) Amyloid-Related Alzheimer's Disease Phase 1 Breaking News ...
PrivateSan Francisco, United States
St Petersburg, United States
Sylvia Villeneuve on Synergistic Effect of β-Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals.
COMMENT This study by Mormino et al. addresses important questions using an elegant methodology. In order to use cognition as an endpoint in clinical trials enrolling cognitively normal older adults, it is important to assess the relationship between the AD ...
No filters selected